Comparative efficacy and safety of tofacitinib, baricitinib, upadacitinib, filgotinib and peficitinib as monotherapy for active rheumatoid arthritis.

Published in: Journal of clinical pharmacy and therapeutics (2020)

All five JAK inhibitors-tofacitinib, baricitinib, upadacitinib, filgotinib and peficitinib-were efficacious monotherapy interventions for active RA, and differences were noted in their efficacy and safety in monotherapy.

Keyphrases

rheumatoid arthritis
combination therapy
disease activity
open label
interstitial lung disease
ankylosing spondylitis
physical activity
ulcerative colitis
systemic sclerosis